← Eichor
Study identifier: NCT07099859 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Effect of Losartan on the Neurohumoral Axis and Ventricular Remodeling of Patients With Severe Aortic Regurgitation Undergoing Valve Surgery.

Condition: Heart Valve Diseases · Left Ventricle Remodeling · Aortic Regurgitation Disease  ·  Sponsor: Vitor Emer Egypto Rosa

PhasePhase 4
Planned participants60
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

Why Is This Study Important? The heart has valves that help control blood flow. Aortic regurgitation (AR) is a condition where one of these valves (the aortic valve) doesn't close properly, causing blood to leak back into the heart. Over time, this makes the heart work harder and grow larger (remodeling) to keep up. Many patients with severe AR need valve replacement surgery to fix this problem. After surgery, the heart doesn't have to work as hard, and over time, it can shrink back to a healthier size (reverse remodeling). However, doctors don't know if medications can help speed up or improve this healing process. This study aims to find out if a common blood pressure medication, losartan, can help the heart recover better after surgery. What Do the Investigators Already Know? Doctors often prescribe medications like ACE inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and spironolactone to people with heart failure because these drugs help the heart function better and prevent worsening disease. However, these medications haven't been studied in people with valve disease because most major research studies excluded patients with valve problems. Even though there is not strong evidence, many doctors prescribe these medications after valve surgery, assuming they might be helpful. But is that really the case? That's the question this study hopes to answer. What Is This Study About? This study will test whether losartan, a medication often used for high bl…

This description comes directly from the study's public registry record.

Talk to the study team

Vitor E. E. Rosa, MD, PhD  ·  551126613653  ·  vitor.rosa@hc.fm.usp.br

Mariana P Lopes, MD  ·  551126611548  ·  mari.pezzutelopes@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Heart Institute of the School of Medicine of the University of São PauloSão Paulo, São Paulo, BrazilRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07099859